Clinical Trial Update: Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults [Phase 2]

View source ↗

Summary

Phase 2 dose-finding trial completed evaluating safety and immunogenicity of the CMV vaccine mRNA-1647 in healthy adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• mRNA-1647 (Cytomegalovirus vaccine (mRNA-1647))

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Cytomegalovirus Infection | Phase 2 | Status: COMPLETED